Biosimilars Market by Product, Indication and Region

DUBLIN, November 10, 2021 / PRNewswire / – The “Global Biosimilars Market by Product (Monoclonal Antibodies (infliximab, Rituximab, Trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Forecast Until in 2026 “ report was added to offer.

Research and Markets logo

The global biosimilars market is expected to reach $ 44.7 billion by 2026 from $ 15.6 billion in 2021, at a CAGR of 23.5% over the forecast period 2021 to 2026.

The growth of the market is largely driven by the increasing incidence of chronic diseases and the increasing demand for biosimilars for their cost effectiveness. Regulatory approvals and other regulations favoring the adoption of biosimilars in different countries are also a determining factor in the biosimilars market. However, the complexities of biosimilar development and manufacture and resistance from manufacturers of reference biologics are expected to constrain the growth of this market during the forecast period.

The monoclonal antibody products segment accounted for the highest growth rate of the biosimilars market, by product, during the forecast period.

In 2020, the monoclonal antibody product segment accounted for the largest share (27.5%) of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and their wide use in the treatment of cancer, autoimmune diseases, and osteoporosis. They are also used in indications such as rheumatoid arthritis, multiple sclerosis and macular degeneration. The growth of the fastest growing segment has been attributed to the increasing incidence of cancer and chronic disease cases and the growth of the geriatric population.

The oncology segment accounted for the largest share of the indications segment

Based on the indication, the biosimilars market is segmented into Oncology, Inflammatory and Autoimmune Diseases, Chronic Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic renal failure and ophthalmic diseases). Oncology is the most important segment of this market due to the availability of biosimilars at a lower price than innovative biologics and a large number of cancer patients.

The availability of biosimilars in the field of oncology has lowered prices and made cancer treatment more affordable and accessible. Additionally, due to the high incidence and prevalence of cancer, health systems around the world are focused on reducing the burden of cancer by adopting cost-effective treatment options. In this scenario, biosimilar drugs could be widely adopted in major markets such as the United States, Europe, and the Asia Pacific. Given these factors and the growing competition from biosimilars, many large biologic pharmaceutical companies are investing heavily in the development and approval of biosimilar drugs.

Asia Pacific: The fastest growing region in the biosimilars market

The biosimilars market is segmented into Europe, Asia Pacific, North America, Latin America and Middle East and Africa. The APAC market, on the other hand, is expected to be the fastest growing regional segment during the forecast period owing to the presence of many emerging players, less stringent regulations, and increasing cooperation among major regional players. for the development, manufacture and marketing of biosimilars.

Main topics covered:

1. Introduction

2 Research methodology

3 Executive summary

4 premium information
4.1 Biosimilars Market Overview
4.2 North America: Biosimilars market, by product and by country (2020)
4.3 Geographic Overview of the Biosimilars Market

5 Market overview
5.1 Presentation
5.2 Market dynamics
5.2.1 Drivers Growing demand for biosimilar drugs due to their cost effectiveness Growing Geriatric Population and Rising Incidence of Chronic Diseases Abbreviated Regulatory Approval Process and Concept of Interchangeability
5.2.2 Constraints Manufacturing complexities Resistance from manufacturers of organic products
5.2.3 Opportunities Emerging markets Patent expiration of successful biologics and research into new indications
5.2.4 Challenges Excess competition
5.2.5 Trends Collaborations for Biosimilar Research and Clinical Trials
5.3 COVID-19 impact assessment
5.4 Technological analysis
5.5 Value chain analysis
5.6 Ecosystem Market Map
5.7 Supply chain analysis
5.8 Porter’s five forces analysis
5.8.1 Threat of new entrants
5.8.2 Threat of substitutes
5.8.3 Bargaining Power of Suppliers
5.8.4 Bargaining power of buyers
5.8.5 Intensity of competitive rivalry
5.9 Regulatory landscape

6 Biosimilars market, by product
6.1 Presentation
6.2 Monoclonal antibodies
6.2.1 Infliximab Infliximab accounted for the largest share of the monoclonal antibody market
6.2.2 Trastuzumab Growing Incidence of Cancer to Drive Market Growth
6.2.3 Rituximab Growing Incidence of Autoimmune Diseases and Cancer Are Key Drivers of Market Growth
6.2.4 Adalimumab Adalimumab will register the highest CAGR in the monoclonal antibody market
6.2.5 Other monoclonal antibodies
6.3 Insulin
6.3.1 Increasing Incidence of Diabetes to Support Market Growth
6.4 Granulocyte colony stimulating factor
6.4.1 G-Csf is used to treat cancer patients with neutropenia occurring after chemotherapy
6.5 Erythropoietin
6.5.1 Increasing Incidence of Blood Disorders Will Drive Market Growth
6.6 Recombinant human growth hormone
6.6.1 Market Growth is Mainly Due to Rising Incidence of Growth Disorders
6.7 Etanercept
6.7.1 APAC will witness the highest growth of etanercept market during the forecast period
6.8 Follitropin
6.8.1 Growing Application of Follitropin in Infertility Treatment to Drive Market Growth
6.9 Teriparatide
6.9.1 The Rise In Osteoporosis Incidence Is The Main Growth Driver Of The Market
6.10 Interferons
6.10.1 Increasing Infectious Disease Incidence To Support Market Growth
6.11 Enoxaparin sodium
6.11.1 A wide range of applications have supported the demand for enoxaparin sodium biosimilars
6.12 Glucagon
6.12.1 Sandoz is a Major player in the glucagon biosimilars market
6.13 Calcitonin
6.13.1 Increasing Incidence of Osteoporosis to Drive Market Growth

7 Biosimilars market, by indication
7.1 Presentation
7.2 Oncology
7.2.1 Growing cancer burden to drive demand for biosimilars
7.3 Inflammatory and autoimmune diseases
7.3.1 Changes in lifestyle and environmental conditions have increased the incidence of inflammatory and autoimmune diseases
7.4 Chronic diseases
7.4.1 Global High Burden of Cvd and Diabetes to Drive Market Growth
7.5 Blood disorders
7.5.1 The increased incidence of blood disorders has increased the demand for biosimilars for this indication segment
7.6 Growth hormone deficiency
7.6.1 Growing Use Of Biosimilars For Treatment Of This Medical Condition To Support Market Growth
7.7 Infectious diseases
7.7.1 The biosimilars market for infectious diseases is expected to be the highest in the world Asia Pacific
7.8 Other indications

8 Biosimilars Market, by Region

9 Competitive landscape
9.1 Presentation
9.2 Right to win approach
9.3 Revenue Share Analysis of Major Market Players
9.4 Market share analysis
9.5 Company valuation quadrant
9.5.1 Stars
9.5.2 Emerging leaders
9.5.3 Omnipresent actors
9.5.4 Participants
9.6 Business valuation quadrant: start-up / SME
9.6.1 Progressive companies
9.6.2 Starting blocks
9.6.3 Responsive companies
9.6.4 Dynamic businesses
9.7 Competitive benchmarking
9.7.1 Company product footprint
9.7.2 Company indication imprint
9.7.3 Regional footprint of the company
9.8 Growth strategies adopted by emerging and key players
9.8.1 Product launches and approvals
9.8.2 Offers
9.8.3 Other developments

10 company profiles
10.1 Major players
10.1.1 Novartis AG
10.1.2 Pfizer Inc.
10.1.3 Dr. Reddy’s Laboratories Ltd.
10.1.4 Amgen Inc.
10.1.5 Eli Lilly and Company
10.1.6 Teva Pharmaceutical Industries Ltd.
10.1.7 Fresenius Se & Co. KGaA
10.1.8 Stada Arzneimittel AG
10.1.9 Boehringer Ingelheim
10.1.10 Gideon Richter plc
10.1.11 Celltrion
10.1.12 Samsung organic products
10.1.13 Coherus Biosciences
10.1.14 Biocon Limited
10.1.15 Viatris
10.2 Other players
10.2.1 Amega Biotech
10.2.2 Apotex Inc.
10.2.3 Biocad
10.2.4 Mabxience
10.2.5 Probiomed SA De CV
10.2.6 Fujifilm Kyowa Kirin Biologics Co., Ltd.
10.2.7 Intas Pharmaceuticals Ltd.
10.2.8 Theramex
10.2.9 Reliance Life Sciences
10.2.10 Kashiv Biosciences

11 Appendix

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716



Show original content:—global-forecast-to-2026-301421025.html

SOURCE Research and Markets

Source link

About Michael Bill

Check Also

BMS Anemia Drug Reblozyl Arrives Fast in Korea

BMS Reblozyl (ingredient: luspatercept) anemia treatment hit the Korean market only two and …

Leave a Reply

Your email address will not be published.